Imprivata, Inc.

Robbins LLP Is Investigating the Officers and Directors of Imprivata, Inc. (IMPR) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Imprivata, Inc. (NYSE: IMPR) violated federal securities laws by issuing materially misleading business information to the investing public. Imprivata provides authentication and access management technology solutions for the healthcare industry in the United States, United Kingdom, and internationally.

Imprivata Discloses Disappointing Financial Results

On June 25, 2014, Imprivata stock traded as high as $17.49, the day the company sold 5 million shares of stock in its initial public offering (“IPO”), raising $75 million in new capital. Then, on October 14, 2015, after the close of trading, Imprivata issued a press release disclosing disappointing preliminary third quarter 2015 financial results that fell below the company’s expectations. The company further announced that some of its large deals were delayed due to customer implementation schedules and available IT resources, which led to lower than expected revenue growth. That same day, after the market closed, the company’s earnings and revenue guidance were significantly lowered from consensus estimates. Since its IPO, Imprivata’s stock has fallen almost 50% from its high of $21.63 on August 19, 2015 to trade at $10.88 on October 29, 2015.

Imprivata Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.